Tiresias: The Roadmap

"The technology is unstoppable. The future is bright."

Naval Ravikant

My friends,

Many of Tiresias’s posts has been giving Tiresias’s vision of in vivo, real-time, AI assisted, digital pathology. Tiresias has used words and asked you his friends to use their imagination and picture his vision in your mind’s eye Tiresias’s vision. But it is no longer necessary just to imagine. Now my friends, if you have watched the Zeiss in vivo CONVIVO Pathology Suite you have seen Tiresias’s vision and you have also seen the future. If you have not seen it yet, please do so, and if you have seen it look at it again and again. This is the revolution that is taking place. Seamless digital pathology consultation, with real time neuropathology, and collaborative interaction of the neurosurgeon and the neuropathologist, at a distance with artificial intelligence assistance to finally get proper and complete surgical resection of the malignant cells from the brain. This is how it’s going to be done not just for brain tumour surgery but for all cancer surgery, and not just for surgery but for the much much bigger field of cancer diagnosis in the clinic.

Zeiss have done a great service for Optiscan and for Optiscan’s loyal shareholders in producing this roadmap. Carl Zeiss started with the most difficult the most challenging area of surgery in in vivo real time digital pathology of malignant brain tumours. As Tiresias has said before, there has been no improvement in glioblastoma multiforme survival in the last fifty years. This will make a difference to survival, and brain tumour surgery will not be ethical without the CONVIVO, once this is established. Zeis will then be able to retool the entire neurosurgical operating equipment around the world, of which they already have about 80% of the market, to incorporate the CONVIVO. They have taken their time in a typical Teutonic precision instrument maker style, making sure that every step is right and there are no setbacks. Now, all Optiscan has to do is to replicate what Zeiss is doing with brain tumour surgery in every other area of cancer diagnosis and cancer surgery, in the clinic and in the operating theatre. The roadmap is there, the road ahead is clear, the rewards for success will be well out of this world. Tiresias would grasp this vision and immediately follow, by whatever means necessary, starting with low hanging fruit with Mohs Surgery for skin cancer, oral cancer, breast cancer and cancer of the cervix. We have the technology, the vision is there, there is money, and there are other “Zeisses” in other areas who will jump in and collaborate. Bring it on.